a senior partner at McKinsey in Hong Kong, was quoted by FT. Xiaobin Wu, Ph.D., formerly Pfizer China’s general manager who recently jumped to BeiGene, told FT that at Chinese biotech startups, “the working dynamic is very different and the decision …
( read original story …)